Hyperglycinemia, Nonketotic
Hyperglycemic Hyperosmolar Nonketotic Coma
Aminomethyltransferase
Glycine Decarboxylase Complex H-Protein
Glycine Dehydrogenase (Decarboxylating)
Amino Acid Metabolism, Inborn Errors
Glycine
Dyskinesias
Brain Diseases, Metabolic
Chorea
Basal Ganglia Diseases
Localized proton MR spectroscopic detection of nonketotic hyperglycinemia in an infant. (1/18)
Nonketotic hyperglycinemia (NKH) is a rare metabolic brain disease caused by deficient activity of the glycine cleavage system. Localized proton MR spectroscopy (echo-time 166 msec), performed in an infant with the typical clinical and biochemical features of neonatal NKH, showed a markedly increased peak intensity at 3.55 ppm, which was assigned to glycine. Serial proton MR spectroscopic studies indicated that glycine/choline and glycine/total creatine ratios correlated closely with the patient's clinical course. Proton MR spectroscopy was useful for the non-invasive detection and monitoring of cerebral glycine levels in this infant with NKH. (+info)Reflex seizures and non-ketotic hyperglycemia: an unresolved issue. (2/18)
Reflex seizures are a rare form of epilepsy, the pathogenesis of which is unclear. They have been reported in the setting of non-ketotic hyperglycemia (NKH) and are considered to be neuroendocrine in origin. We report a diabetic patient with movement-induced seizures whose presentation suggests that brain ischemia may be the precipitating event in focal seizures seen in the setting of NKH. We recommend that in such instances a focal lesion such as stroke should be ruled out. (+info)Prenatal diagnosis of hypoplasia of the corpus callosum in association with non-ketotic hyperglycinemia. (3/18)
Abnormalities of the corpus callosum are often associated with a poor prognosis due to the anatomical defect itself and associated anomalies that include malformations and inherited metabolic disorders. We report a case of the prenatal diagnosis of hypoplasia of the corpus callosum that was associated with non-ketotic hyperglycinemia. Metabolic disorders are a known association with corpus callosum abnormalities and carry a dismal prognosis. A diagnosis of non-ketotic hyperglycinemia should be considered when a fetus presents with an abnormality of the corpus callosum. A literature search reviews other inherited diseases associated with hypoplasia of the corpus callosum. (+info)Diffusion-weighted MR imaging in neonatal nonketotic hyperglycinemia. (4/18)
To our knowledge, we are the first to report the diffusion-weighted MR imaging findings in a 15-day-old neonate with nonketotic hyperglycinemia. We found bilaterally symmetrical lesions of restricted diffusion in the dorsal brain stem, cerebral peduncles, and posterior limbs of the internal capsule, which were more conspicuous and extensive on diffusion-weighted MR images than on T2-weighted images. These lesions are in the myelinated tracts of the neonate and are compatible with the expected sites of abnormality in vacuolating myelinopathy. (+info)Unilateral putaminal CT, MR, and diffusion abnormalities secondary to nonketotic hyperglycemia in the setting of acute neurologic symptoms mimicking stroke. (5/18)
A 75-year-old Asian man presented with two episodes of chorea associated with nonketotic hyperglycemia. His chorea rapidly resolved after restitution of a normal serum glucose level, although an MR image obtained at the time of acute symptoms demonstrated high signal intensity on T1-weighted images, low signal intensity on T2-weighted images, and restricted diffusion, all involving the left putamen. A CT scan obtained 1 month later demonstrated faint hyperattenuation of the involved putamen. The reported pathophysiologic considerations for these imaging features are reviewed, and an original explanation is proposed. (+info)Crystal structure of T-protein of the glycine cleavage system. Cofactor binding, insights into H-protein recognition, and molecular basis for understanding nonketotic hyperglycinemia. (6/18)
The glycine cleavage system catalyzes the oxidative decarboxylation of glycine in bacteria and in mitochondria of animals and plants. Its deficiency in human causes nonketotic hyperglycinemia, an inborn error of glycine metabolism. T-protein, one of the four components of the glycine cleavage system,is a tetrahydrofolate dependent aminomethyltransferase. It catalyzes the transfer of the methylene carbon unit to tetrahydrofolate from the methylamine group covalently attached to the lipoamide arm of H-protein. To gain insight into the T-protein function at the molecular level, we have determined the first crystal structure of T-protein from Thermotoga maritima by the multiwavelength anomalous diffraction method of x-ray crystallography and refined four structures: the apoform; the tetrahydrofolate complex; the folinic acid complex; and the lipoic acid complex. The overall fold of T-protein is similar to that of the C-terminal tetrahydrofolate-binding region (residues 421-830) of Arthrobacter globiformis dimethylglycine oxidase. Tetrahydrofolate (or folinic acid) is bound near the center of the tripartite T-protein. Lipoic acid is bound adjacent to the tetrahydrofolate binding pocket, thus defining the interaction surface for H-protein binding. A homology model of the human T-protein provides the structural framework for understanding the molecular mechanisms underlying the development of nonketotic hyperglycinemia due to missense mutations of the human T-protein. (+info)Structure of P-protein of the glycine cleavage system: implications for nonketotic hyperglycinemia. (7/18)
The crystal structure of the P-protein of the glycine cleavage system from Thermus thermophilus HB8 has been determined. This is the first reported crystal structure of a P-protein, and it reveals that P-proteins do not involve the alpha(2)-type active dimer universally observed in the evolutionarily related pyridoxal 5'-phosphate (PLP)-dependent enzymes. Instead, novel alphabeta-type dimers associate to form an alpha(2)beta(2) tetramer, where the alpha- and beta-subunits are structurally similar and appear to have arisen by gene duplication and subsequent divergence with a loss of one active site. The binding of PLP to the apoenzyme induces large open-closed conformational changes, with residues moving up to 13.5 A. The structure of the complex formed by the holoenzyme bound to an inhibitor, (aminooxy)acetate, suggests residues that may be responsible for substrate recognition. The molecular surface around the lipoamide-binding channel shows conservation of positively charged residues, which are possibly involved in complex formation with the H-protein. These results provide insights into the molecular basis of nonketotic hyperglycinemia. (+info)Tonic eye deviation due to nonketotic hyperglycaemia induced focal seizures: case report. (8/18)
We report a case of intermittent tonic conjugate eye deviation due to nonketotic hyperglycaemia induced focal seizure. (+info)Nonketotic hyperglycinemia (NKH) is a rare inherited metabolic disorder characterized by an elevated level of the amino acid glycine in the body due to a deficiency of the enzyme needed to break it down, specifically the glycine cleavage system. This condition leads to developmental delays, seizures, and hypotonia (low muscle tone). The nonketotic part of the name refers to the fact that there is no production of ketones during periods of fasting or illness, which is unusual in disorders associated with elevated glycine levels.
NKH is typically caused by mutations in the GLDC or AMT gene and can be further classified into two types: type I (also known as the classic or severe form) and type II (also known as the attenuated or mild form). Type I NKH usually presents in early infancy with severe symptoms, including seizures, lethargy, and apnea, while type II NKH may present later in childhood with less severe symptoms.
Treatment for NKH is primarily supportive and includes anticonvulsant medications to manage seizures, as well as dietary management to limit glycine intake. In some cases, sodium benzoate or dextromethorphan may be used to reduce glycine levels in the body. However, there is no cure for NKH and prognosis varies depending on the severity of the condition.
Hyperglycemic Hyperosmolar Nonketotic Coma (HHNC) is a serious complication of diabetes, specifically type 2, that occurs when blood glucose levels rise to extremely high levels, typically above 600 mg/dL. This condition is often accompanied by severe dehydration due to excessive urination and an inability to consume adequate fluids.
The term "hyperosmolar" refers to the high concentration of glucose in the blood, which increases the osmolality (or osmotic pressure) of the blood. This can lead to water moving out of cells and into the bloodstream to try to balance out the concentration, causing severe dehydration.
The term "nonketotic" means that there is no significant production of ketone bodies, which are produced when the body breaks down fat for energy in the absence of sufficient insulin. This differentiates HHNC from diabetic ketoacidosis (DKA), another serious complication of diabetes.
The "coma" part of the term refers to the fact that HHNC can cause altered mental status, ranging from confusion and disorientation to coma, due to the effects of dehydration and high blood glucose levels on the brain.
HHNC is a medical emergency that requires immediate treatment in a hospital setting. Treatment typically involves administering fluids to rehydrate the body, insulin to lower blood glucose levels, and addressing any other underlying conditions or complications. If left untreated, HHNC can be life-threatening.
Aminomethyltransferase is an enzyme that plays a role in the metabolism of certain amino acids, specifically methionine and glycine. It catalyzes the transfer of an aminomethyl group from one molecule to another. A deficiency in this enzyme can lead to a rare genetic disorder called nonketotic hyperglycinemia, which is characterized by elevated levels of the amino acid glycine in the body and can cause neurological symptoms such as seizures and developmental delays.
The Glycine Decarboxylase Complex (GDC) is a multienzyme complex that plays a crucial role in the metabolism of glycine, an amino acid. This complex is composed of four main proteins: P-, H-, T- and L-protein. The H-protein, also known as the H protein of the glycine decarboxylase complex or GLDC, is a pyridoxal phosphate (PLP)-dependent enzyme that catalyzes the first step in the glycine cleavage system (GCS).
The GCS is responsible for the oxidative cleavage of glycine to form ammonia, carbon dioxide, and a methyl group, which is then transferred to tetrahydrofolate. The H-protein functions as a dehydrogenase in this process, facilitating the conversion of glycine to aminoacetic acid (also known as β-alanine) and liberating a molecule of CO2.
In summary, Glycine Decarboxylase Complex H-Protein is a key enzyme in the Glycine Decarboxylase Complex that facilitates the oxidative cleavage of glycine, an essential amino acid metabolism pathway.
Inborn errors of amino acid metabolism refer to genetic disorders that affect the body's ability to properly break down and process individual amino acids, which are the building blocks of proteins. These disorders can result in an accumulation of toxic levels of certain amino acids or their byproducts in the body, leading to a variety of symptoms and health complications.
There are many different types of inborn errors of amino acid metabolism, each affecting a specific amino acid or group of amino acids. Some examples include:
* Phenylketonuria (PKU): This disorder affects the breakdown of the amino acid phenylalanine, leading to its accumulation in the body and causing brain damage if left untreated.
* Maple syrup urine disease: This disorder affects the breakdown of the branched-chain amino acids leucine, isoleucine, and valine, leading to their accumulation in the body and causing neurological problems.
* Homocystinuria: This disorder affects the breakdown of the amino acid methionine, leading to its accumulation in the body and causing a range of symptoms including developmental delay, intellectual disability, and cardiovascular problems.
Treatment for inborn errors of amino acid metabolism typically involves dietary restrictions or supplementation to manage the levels of affected amino acids in the body. In some cases, medication or other therapies may also be necessary. Early diagnosis and treatment can help prevent or minimize the severity of symptoms and health complications associated with these disorders.
Glycine is a simple amino acid that plays a crucial role in the body. According to the medical definition, glycine is an essential component for the synthesis of proteins, peptides, and other biologically important compounds. It is also involved in various metabolic processes, such as the production of creatine, which supports muscle function, and the regulation of neurotransmitters, affecting nerve impulse transmission and brain function. Glycine can be found as a free form in the body and is also present in many dietary proteins.
Dyskinesias are a type of movement disorder characterized by involuntary, erratic, and often repetitive muscle movements. These movements can affect any part of the body and can include twisting, writhing, or jerking motions, as well as slow, writhing contortions. Dyskinesias can be caused by a variety of factors, including certain medications (such as those used to treat Parkinson's disease), brain injury, stroke, infection, or exposure to toxins. They can also be a side effect of some medical treatments, such as radiation therapy or chemotherapy.
Dyskinesias can have a significant impact on a person's daily life, making it difficult for them to perform routine tasks and affecting their overall quality of life. Treatment for dyskinesias depends on the underlying cause and may include medication adjustments, surgery, or physical therapy. In some cases, dyskinesias may be managed with the use of assistive devices or by modifying the person's environment to make it easier for them to move around.
Metabolic brain diseases refer to a group of conditions that are caused by disruptions in the body's metabolic processes, which affect the brain. These disorders can be inherited or acquired and can result from problems with the way the body produces, breaks down, or uses energy and nutrients.
Examples of metabolic brain diseases include:
1. Mitochondrial encephalomyopathies: These are a group of genetic disorders that affect the mitochondria, which are the energy-producing structures in cells. When the mitochondria don't function properly, it can lead to muscle weakness, neurological problems, and developmental delays.
2. Leukodystrophies: These are a group of genetic disorders that affect the white matter of the brain, which is made up of nerve fibers covered in myelin, a fatty substance that insulates the fibers and helps them transmit signals. When the myelin breaks down or is not produced properly, it can lead to cognitive decline, motor problems, and other neurological symptoms.
3. Lysosomal storage disorders: These are genetic disorders that affect the lysosomes, which are structures in cells that break down waste products and recycle cellular materials. When the lysosomes don't function properly, it can lead to the accumulation of waste products in cells, including brain cells, causing damage and neurological symptoms.
4. Maple syrup urine disease: This is a genetic disorder that affects the way the body breaks down certain amino acids, leading to a buildup of toxic levels of these substances in the blood and urine. If left untreated, it can cause brain damage, developmental delays, and other neurological problems.
5. Homocystinuria: This is a genetic disorder that affects the way the body processes an amino acid called methionine, leading to a buildup of homocysteine in the blood. High levels of homocysteine can cause damage to the blood vessels and lead to neurological problems, including seizures, developmental delays, and cognitive decline.
Treatment for metabolic brain diseases may involve dietary changes, supplements, medications, or other therapies aimed at managing symptoms and preventing further damage to the brain. In some cases, a stem cell transplant may be recommended as a treatment option.
Chorea is a medical term that describes an involuntary movement disorder characterized by brief, irregular, and abrupt jerky movements. These movements often occur randomly and can affect any part of the body. Chorea can also cause difficulty with coordination and balance, and can sometimes be accompanied by muscle weakness or rigidity.
The term "chorea" comes from the Greek word "χορεία" (khoréia), which means "dance," reflecting the graceful, dance-like movements that are characteristic of this condition. Chorea can occur as a symptom of various underlying medical conditions, including neurological disorders such as Huntington's disease, Sydenham's chorea, and cerebral palsy, as well as metabolic disorders, infections, and certain medications.
Treatment for chorea depends on the underlying cause of the condition and may include medications to help control the involuntary movements, physical therapy to improve coordination and balance, and lifestyle modifications to reduce the risk of injury from falls or other accidents. In some cases, surgery may be recommended as a last resort for severe or refractory chorea.
Basal ganglia diseases are a group of neurological disorders that affect the function of the basal ganglia, which are clusters of nerve cells located deep within the brain. The basal ganglia play a crucial role in controlling movement and coordination. When they are damaged or degenerate, it can result in various motor symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and difficulty with balance and walking.
Some examples of basal ganglia diseases include:
1. Parkinson's disease - a progressive disorder that affects movement due to the death of dopamine-producing cells in the basal ganglia.
2. Huntington's disease - an inherited neurodegenerative disorder that causes uncontrolled movements, emotional problems, and cognitive decline.
3. Dystonia - a movement disorder characterized by sustained or intermittent muscle contractions that cause twisting and repetitive movements or abnormal postures.
4. Wilson's disease - a rare genetic disorder that causes excessive copper accumulation in the liver and brain, leading to neurological and psychiatric symptoms.
5. Progressive supranuclear palsy (PSP) - a rare brain disorder that affects movement, gait, and balance, as well as speech and swallowing.
6. Corticobasal degeneration (CBD) - a rare neurological disorder characterized by progressive loss of nerve cells in the cerebral cortex and basal ganglia, leading to stiffness, rigidity, and difficulty with movement and coordination.
Treatment for basal ganglia diseases varies depending on the specific diagnosis and symptoms but may include medication, surgery, physical therapy, or a combination of these approaches.
Glycine encephalopathy
Glycine dehydrogenase (decarboxylating)
GCSH
Glycine cleavage system
GLRX5
LIAS (gene)
Jennifer Colón
Chris Anderson (cheese roller)
Hyperglycinemia
Ohtahara syndrome
Finnish heritage disease
List of diseases (N)
Congenital disorders of amino acid metabolism
List of MeSH codes (C10)
Hypotonia
List of MeSH codes (C18)
List of MeSH codes (C16)
List of diseases (H)
Glutamate receptor
Aminomethyltransferase
Nonketotic hyperglycinemia: MedlinePlus Genetics
Conferences | The Foundation for Nonketotic Hyperglycinemia
Nonketotic hyperglycinemia NKH
Genotypic and phenotypic features in Turkish patients with classic nonketotic hyperglycinemia | AVESİS
Glycine encephalopathy - Wikipedia
Amino Acid Metabolism Disorders: MedlinePlus
The genetic basis of classic nonketotic hyperglycinemia due to mutations in GLDC and AMT. | Genet Med;19(1): 104-111, 2017 01....
Genetic Brain Disorders | MedlinePlus
Acrodermatitis Enteropathica: Background, Pathophysiology, Etiology of Acrodermatitis Enteropathica
urofacial syndrome - Ontology Browser - Rat Genome Database
Mitochondrial proteome research: the road ahead | Nature Reviews Molecular Cell Biology
Symptomatic Generalized Epilepsy Clinical Presentation: History, Physical Examination, Causes
Acrodermatitis Enteropathica: Background, Pathophysiology, Etiology of Acrodermatitis Enteropathica
Kristina Cusmano-Ozog's Profile | Stanford Profiles
PEDIATRIC NEURORADIOLOGY | American Journal of Neuroradiology
SLC6 Transporter Folding Diseases and Pharmacochaperoning | SpringerLink
Orotidylic acid: Uses, Interactions, Mechanism of Action | DrugBank Online
Child Born With Only 2% Of His Brain Defies All Expectations After It 'Grows Back' - George Takei
2023 ICD-10-CM Diagnosis Code E72.81: Disorders of gamma aminobutyric acid metabolism
Chelmsford Mum tackles Half-Marathon to thank children's hospice that cares for her son - Havens Hospices
Namespace
Family friend's plea to help grieving wife and sons fly dad's body home - Lincolnshire Live
Drakerayden | South Carolina | Drake Rayden Foundation
Johan Van Hove | Children's Hospital Colorado
Randy Rogers Opens Up About Death of Newborn Daughter
Browse Items · Pediatric Palliative Care Library
Aminomethyltransferase | Colorado PROFILES
July 20, 2022 - Patient Worthy
Glycine Encephalopathy4
- Glycine encephalopathy, formerly referred to as nonketotic hyperglycinemia, is a heterogeneous disorder associated with the insufficient activity of various components of the mitochondrial glycine cleavage system. (lucasjohnfoundation.com)
- Glycine encephalopathy is sometimes referred to as "nonketotic hyperglycinemia" (NKH), as a reference to the biochemical findings seen in patients with the disorder, and to distinguish it from the disorders that cause "ketotic hyperglycinemia" (seen in propionic acidemia and several other inherited metabolic disorders). (wikipedia.org)
- In 2019, the Drake Rayden Foundation partnered with the Steven Gray Lab at the University of Texas Southwestern, UTSW for a two year project, to create a gene replacement therapy for the terminal, rare disease NonKetotic Hyperglycinemia, or Glycine Encephalopathy. (drakeraydenfoundation.com)
- BACKGROUND: Glycine encephalopathy, also known as nonketotic hyperglycinemia (NKH), is an autosomal recessive disorder caused by a defect in the glycine cleavage system. (omeka.net)
Classic nonketotic hyperglycinemia2
- The genetic basis of classic nonketotic hyperglycinemia due to mutations in GLDC and AMT. (bvsalud.org)
- The study's purpose was to delineate the genetic mutations that cause classic nonketotic hyperglycinemia (NKH). (bvsalud.org)
Ketotic hyperglycinemia6
- Non-ketotic hyperglycinemia (NKH) is a rare, genetic, metabolic disorder caused by a defect in the GLDC or AMT gene code which affects the enzyme system that breaks down the amino acid glycine, resulting in an accumulation of glycine in the body's tissues and fluids. (lucasjohnfoundation.com)
- One parent related to Shelly and Rob's experience and shared his own story about the daughter he almost lost to Non- ketotic hyperglycinemia (NKH), a metabolic disorder. (georgetakei.com)
- Her son Mason, two, was born with a rare genetic, metabolic condition NKH (Non-Ketotic Hyperglycinemia) which means his body cannot process glycine. (havenshospices.org.uk)
- I am interested in neurometabolic diseases that causes seizures, in particular in non-ketotic hyperglycinemia. (childrenscolorado.org)
- View my research website on non-ketotic hyperglycinemia: https://medschool.cuanschutz.edu/pediatrics/sections/genetics-and-metabolism/research/nonketotic-hyperglycinemia-(nkh)-research-lab I study disorders of cellular energetics in particular mitochondrial disorders, and fatty acid oxidation disorders. (childrenscolorado.org)
- She was born in 2018 with a rare disease, Non-ketotic hyperglycinemia (NKH). (islarosefoundation.com)
Metabolic2
- Metabolic acidosis and/or hyperammonemia are observed in many of these conditions, but there are notable exceptions, including nonketotic hyperglycinemia and molybdenum co-factor deficiency. (northwestern.edu)
- Here's the kicker though - despite being chromosomally perfect our little guy inherited an incredibly rare metabolic disorder called Nonketotic Hyperglycinemia. (hopeandhopscotch.com)
Autosomal recessive disorder1
- Multiple mitochondrial dysfunctions syndrome-2 (MMDS2) with hyperglycinemia is a severe autosomal recessive disorder characterized by developmental regression in infancy. (nih.gov)
Mutations2
- Mutations in the GLDC or AMT gene cause nonketotic hyperglycinemia. (medlineplus.gov)
- GLDC or AMT gene mutations that completely eliminate the system's activity result in severe nonketotic hyperglycinemia, while mutations that preserve some activity cause attenuated nonketotic hyperglycinemia. (medlineplus.gov)
Disorders1
- Please visit my lab research web page at For nonketotic hyperglycinemia (NKH): https://medschool.cuanschutz.edu/pediatrics/sections/genetics-and-metabolism/research/nonketotic-hyperglycinemia-(nkh)-research-lab For Mitochondrial energetics disorders: https://medschool.cuanschutz.edu/pediatrics/sections/genetics-and-metabolism/research/mitochondrial-bioenergetics-disorders-lab I am interested in neurometabolic diseases that causes seizures, in particular in non-ketotic hyperglycinemia. (childrenscolorado.org)
Disorder characterized1
- Nonketotic hyperglycinemia is a disorder characterized by abnormally high levels of a molecule called glycine in the body (hyperglycinemia). (medlineplus.gov)
20171
- Founded in 2017 to provide information and support to families with living with Nonketotic Hyperglycinemia (NKH). (foundationnkh.org)
Developmental2
- Children with attenuated nonketotic hyperglycinemia typically reach developmental milestones, although the skills they achieve vary widely. (medlineplus.gov)
- It is unclear how these abnormalities contribute to the developmental disability, seizures, breathing difficulties, and other features characteristic of nonketotic hyperglycinemia. (medlineplus.gov)
Severe3
- Nonketotic hyperglycinemia has two forms, the severe form and the attenuated form. (medlineplus.gov)
- Severe nonketotic hyperglycinemia is more common. (medlineplus.gov)
- The signs and symptoms of the attenuated form of nonketotic hyperglycinemia are similar to, but milder than, those of the severe form of the condition. (medlineplus.gov)
Foundation1
- The Drake Rayden Foundation has funded $294,016 .10 to date for T reatment D riven R esearch for children with NonKetotic Hyperglycinemia, (NKH). (drakeraydenfoundation.com)
Result1
- It was the second tragedy to befall the family, who lost their six-year-old daughter Lyla Mae, who passed away as a result of Nonketotic Hyperglycinemia 14 months ago. (lincolnshirelive.co.uk)
Infant with nonketotic hype1
- Acrodermatitis enteropathica-like eruption in an infant with nonketotic hyperglycinemia. (medscape.com)
Variants of nonketotic hyperglycinemia1
- The variants of nonketotic hyperglycinemia. (albionfoundation.org)
Ketotic8
- Glycine encephalopathy is sometimes referred to as "nonketotic hyperglycinemia" (NKH), as a reference to the biochemical findings seen in patients with the disorder, and to distinguish it from the disorders that cause "ketotic hyperglycinemia" (seen in propionic acidemia and several other inherited metabolic disorders). (wikipedia.org)
- Concurrent non-ketotic hyperglycinemia and propionic acidemia in an ei" by Paul Kruszka, Brian Kirmse et al. (gwu.edu)
- This is the first reported case of a patient with both non-ketotic hyperglycinemia and propionic acidemia. (gwu.edu)
- Late onset non-ketotic hyperglycinemia - a rare presentation in children. (pakmedinet.com)
- This structural abnormality in the H-protein is considered to constitute the primary molecular lesion in this patient with non-ketotic hyperglycinemia. (lookfordiagnosis.com)
- Case Report: A Variant Non-ketotic Hyperglycinemia With GLRX5 Mutations: Manifestation of Deficiency of Activities of the Respiratory Chain Enzymes. (bibliome.ai)
- It was found that Koleton had a rare metabolic disorder called Non -ketotic hyperglycinemia or NKH, which is an autosomal recessive metabolic disorder characterized by abnormally high levels of amino acid glycine. (onebrightstar.org)
- Eleni was diagnosed with a rare metabolic condition Non ketotic Hyperglycinemia (NKH for short) NKH affects 1 child in every 76,000 born there are approximately 15 kids in the UK and 500 worldwide living with this condition. (sullivansheroes.org)
Inborn error of glycine metabolism2
- Nonketotic hyperglycinemia (NKH) is the inborn error of glycine metabolism defined by deficient activity of the glycine cleavage enzyme system (GCS), which results in accumulation of large quantities of glycine in all body tissues including the brain. (nih.gov)
- Glycine encephalopathy, also known as nonketotic hyperglycinemia (NKH), is an inborn error of glycine metabolism caused by defects in the glycine cleavage multi-enzyme system (GCS) (Hamosh et al. (preventiongenetics.com)
Cleavage4
- Hyperglycinemia in the neonatal and infantile atypical NKH, similar to the classical form, is caused by a deficient glycine cleavage system, whereas the cause of hyperglycinemia in late onset atypical NKH is unknown. (nih.gov)
- Nonketotic hyperglycinemia (NKH) is caused by deficient glycine cleavage enzyme activity and characterized by elevated brain glycine. (emory.edu)
- Defective glycine cleavage system in nonketotic hyperglycinemia. (lookfordiagnosis.com)
- The activities of then glycine cleavage system in the liver and brain of patient with nonketotic hyperglycinemia was extremely low as compared with those of control human liver and brain . (lookfordiagnosis.com)
Glycine levels1
- The authors thank Drs S. Wortmann and H. Björneson who provided information on their patients with transient nonketotic hyperglycinemia or ischemic brain damage with increased CSF glycine levels. (emory.edu)
Gene1
- Defects in this gene are a cause of nonketotic hyperglycinemia (NKH). (nih.gov)
Findings2
- 16. Nonketotic hyperglycinemia: spectrum of imaging findings with emphasis on diffusion-weighted imaging. (nih.gov)
- Esphie Grace D. Fodra, Judy S. Manliguis, Cristine P. Lopez, Mary Anne D. Chiong (2016) Biochemical Findings in the first Filipino Child confirmed to have Nonketotic hyperglycinemia. (edu.ph)
Aciduria1
- d-Glyceric aciduria does not cause nonketotic hyperglycinemia: A historic co-occurrence. (ucdenver.edu)
Disorder1
- Nonketotic hyperglycinemia is a disorder characterized by abnormally high levels of a molecule called glycine in the body (hyperglycinemia). (medlineplus.gov)
Congenital1
- Perinatal asphyxia (13), tuberous sclerosis (2), cortical dysplasia (2), encephalitis (1), asphyxia due to aspiration (1), congenital cytomegalovirus infection (1), perinatal infarct (1), nonketotic hyperglycinemia (1) and Prader Willi syndrome (1) were the identified causes. (jceionline.org)
Features1
- It is unclear how these abnormalities contribute to the developmental disability, seizures, breathing difficulties, and other features characteristic of nonketotic hyperglycinemia. (medlineplus.gov)
Brain1
- Individuals with nonketotic hyperglycinemia can also have certain changes in the brain, which can be seen using magnetic resonance imaging (MRI). (medlineplus.gov)
Children1
- Children with attenuated nonketotic hyperglycinemia typically reach developmental milestones, although the skills they achieve vary widely. (medlineplus.gov)